About Us
Inspired by the unique properties of alpaca-derived nanoantibodies
Our History
“We have developed one of the fastest and most effective methods for identifying highly specific and high-affinity nanoantibodies.”
In 2017, Dr. Alejandro Rojas-Fernandez founded an advanced nanoantibodies platform targeting the Hantavirus Andes strain in Chile. His team identified three nanobody superfamilies to neutralize this unique virus transmitted by specific Andean rodents.
Amidst the global pandemic, Dr. Rojas’s collaborative efforts with Australian researchers led to substantial breakthroughs, discovering potent nanobodies against the threatening Nipah and Hendra viruses, thus broadening the scope of their impactful virology research.
Founded in 2023 in Hamburg, Berking Theranostics was established with the vision to revolutionize cancer care through precision medicine. Inspired by the unique properties of alpaca-derived nanobodies, we have developed a pioneering platform that redefines Theranostics.
Vasko Kramer, PhD
Chief Scientific Officer
Dr. Vasko Kramer holds a PhD in Radiopharmaceutical Chemistry from Johannes Gutenberg University Mainz and currently serves as Chief Scientific Officer at Berking Theranostics. With over a decade of experience in radioligand development and preclinical programs, he leads Berking’s scientific strategy and innovation pipeline. Prior to this, he played a key role in the early-stage development and clinical translation of diagnostic and therapeutic radiopharmaceuticals at Positronpharma SA and Positronmed Ltda, significantly advancing radiopharmacy across Latin America.
Driven by a clear vision, Dr. Kramer is guiding Berking to the forefront of precision oncology, focused on delivering next-generation cancer therapies that make a meaningful impact on patients worldwide.
Anne Berking, PhD
Founder, Berking Biotechnology
Dr. Anne Berking holds a PhD in Infection Biology from the University of Konstanz, followed by postdoctoral research at the University of Dundee in the UK. She later specialized in medical communication and pharmacovigilance, focusing on the reporting of pharmaceutical side effects.
In 2017, Dr. Berking founded Berking Biotechnology in Chile, where she successfully secured seven innovation grants and played a key role in advancing the development of nanoantibodies. Her work helped bring this cutting-edge technology to the forefront of biotech innovation.
Today, she focuses on competitive intelligence and strategic marketing, driving growth and positioning within the global biotechnology landscape.
Alejandro Rojas-Fernandez
With a solid background in Molecular Biotechnology from the University of Chile, Dr. Rojas-Fernandez enhanced his expertise with a DAAD scholarship-aided Ph.D. in Biochemistry in Germany, followed by a productive postdoctoral stint in the UK. Returning to Chile in 2016, he joined the Faculty of Medicine in Valdivia, cementing his academic career which boasts extensive research funding, numerous patents, and significant scientific publications.
Dr. Rojas ascended to global prominence during the pandemic, being the first to create nanobodies against the coronavirus, leading to widespread media coverage and esteemed honors from his home city. Beyond his scientific impact, he’s a celebrated science communicator and is gearing up to publish a unique molecular biology book for kids and alpacas by 2025.
Advisory Board
Guided by Experts, Driven by Excellence
Our advisory board includes leading scientists, oncologists, and industry experts who provide strategic insights and guidance to ensure our innovations meet the highest standards of scientific and clinical excellence.
Prof. Dr. Gopal Sapkota
MRC PPU UK , University of Dundee, Scotland
Prof. Dr. med. Hans-Jürgen Biersack
University of Bonn
Let's share our challenges